Sandoz’s Erelzi (etanercept, biosimilar) Receives Health Canada Approval for Psoriatic Arthritis (PsA) in Adults
Sandoz’s Erelzi (etanercept, biosimilar) Receives Health Canada Approval for Psoriatic Arthritis (PsA) in Adults
Shots:
- The approval is based on P-III EGALITY study results assessing Erelzi (etanercept) vs Enbrel, evaluating its PK, safety and efficacy
- On 17 Jan, 2019 Sandoz received NOC from Health Canada for Erelzi for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis & improving physical function in adults with PsA, in combination with methotrexate who do not respond to methotrexate as monothx
- Erelzi (etanercept, biosimilar) is a mAb, available as a pre-filled syringe (PFS) & pre-filled pen (PFP) in 25 mg and 50 mg PFS, approved by Health Canada for moderately to severely active RA & reducing signs and symptoms of moderately to severely active polyarticular JIA in April, 2017
Click here to read full press release/ article | Ref: Globe News Wire | Image: Pharmacy Boardroom
